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Abstract: Typical Rho GTPases, like Rac1, Cdc42 and RhoA, act as molecular switches regulating 16 
various aspects of platelet cytoskeleton reorganization. The loss of these enzymes results in 17 
reduced platelet functionality. Atypical Rho GTPases of the RhoBTB subfamily are characterised 18 
by divergent domain architecture. One family member, RhoBTB3, is expressed in platelets, but its 19 
function is unclear. In the present study we examined the role of RhoBTB3 in platelet function 20 
using a knockout mouse model. We found the platelet count, size, numbers of both alpha and 21 
dense granules and surface receptor profile in these mice were comparable to wild type mice. 22 
Deletion of Rhobtb3 had no effect on aggregation and dense granule secretion in response to a 23 
range of agonists including thrombin, collagen and ADP. By contrast, alpha granule secretion was 24 
increased in mice lacking RhoBTB3 in response to thrombin, CRP and U46619/ADP. Integrin 25 
activation and spreading on fibrinogen and collagen under static conditions were also 26 
unimpaired, however we observed reduced platelet accrual on collagen under flow conditions. 27 
These defects did not translate into alterations in tail bleeding time. We conclude that genetic 28 
deletion of Rhobtb3 leads to subtle alterations in alpha granule secretion and adhesion to collagen 29 
without significant effects on haemostasis in vivo. 30 
 31 
Keywords: adhesion; collagen; platelets; Rho GTPases; RhoBTB3 32 
 33 
1. Introduction 34 
Activation of blood platelet receptors by thrombogenic proteins present in the extracellular 35 
matrix initiates a multistep process that involves numerous fine-tuned signalling events, leading to 36 
rapid platelet adhesion, degranulation and aggregation [1]. Rho GTPases are molecular switches 37 
that play critical roles in platelet function, regulating the dynamics of the actin cytoskeleton, 38 
aggregation, secretion, spreading and thrombus formation [2]. Platelets contain several classical 39 
Rho GTPases which have been shown to influence platelet function and thrombosis primarily in 40 
mouse models [2,3]. Rac1 is required for lamellipodia formation and platelet spreading 41 
downstream of GPVI and protease activated receptors (PARs) and possibly also for secretion [4]. 42 
The role of Cdc42 is controversial due to conflicting observations from two different mouse models 43 
regarding its participation in filopodia formation, spreading, secretion and aggregation [5,6]. 44 
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Platelets lacking RhoA revealed a requirement of this protein for integrin activation, granule 45 
secretion and clot retraction [7]. No clear role has been identified for Rif [8], while RhoG appears 46 
important for integrin activation, aggregation and secretion in response to GPVI agonists [9,10]. 47 
 48 
RhoBTB proteins are atypical Rho GTPases and as such they differ from classical Rho GTPases 49 
in their regulation and/or domain architecture. More specifically, atypical Rho GTPases do not 50 
follow the classic cycle of activation and inhibition facilitated by guanine nucleotide exchange 51 
factors and GTPase activating proteins, but are regulated at protein expression levels or by specific 52 
protein-protein interactions [11]. RhoBTB proteins are characterised by a carboxyl terminal 53 
extension capable of assembling cullin 3-dependent ubiquitin ligase complexes [12]. Although their 54 
cellular roles are not fully elucidated, it is clear that unlike classical Rho GTPases these proteins 55 
bear no apparent relationship to direct remodeling of the cytoskeleton. RhoBTB proteins are 56 
implicated in tumourigenesis through regulation, among others, of the cell cycle and apoptosis 57 
(reviewed in [12]). RhoBTB3 additionally appears to be implicated in aspects of vesicle trafficking, 58 
like retrograde transport to the Golgi and endosome to lysosome trafficking [13][14]. We have 59 
shown that RhoBTB3 deficient animals are characterised by a postnatal growth defect, reduced 60 
testis size in the males and deficient fertility [15]. All three members of the RhoBTB subfamily are 61 
present in platelets at mRNA levels [16] but the potential relevance of RhoBTB proteins for platelet 62 
function has not been investigated to date. Using a RhoBTB3 knockout (KO) model we extend our 63 
previous report by an in depth characterisation of platelet function using a battery of conventional 64 
functional assays. Our data shows that the loss of RhoBTB3 is associated with altered alpha granule 65 
secretion and a defect in collagen-mediated accrual, but otherwise this protein appears to be 66 
dispensable for haemostasis in vivo. 67 
2. Materials and Methods 68 
Reagents  69 
Iscove’s Modified Dulbecco’s Medium (IMDM) was from Gibco/ThermoFisher Scientific 70 
(Loughborough, UK). Recombinant human erythropoietin and murine interleukin 3 were from 71 
PeproTech (London, UK). BD Fix and Lyse and P-selectin were from BD Biosciences (Oxford, UK). 72 
GFOGER and collagen related peptide (CRP) were from Cambridge University (Cambridge, UK). 73 
Thrombin, ADP, fibrinogen, Gly-Pro-Arg-Pro-NH2, D-Phe-Pro-Arg-chloromethylketone (PPACK) 74 
and TRITC-conjugated phalloidin were from Sigma-Aldrich (Dorset, UK). Collagen reagent Horm 75 
was from Takeda (Osaka, Japan). Heparin sodium was from Leo Laboratories Limited (Berkshire, 76 
UK).  77 
 78 
Cultivation of MKD1 cell line 79 
The murine megakaryocytic cell line MKD1 clone G10 [17] was cultivated in IMDM 80 
supplemented with 10% fetal bovine serum, 2 mM L-glutamine, 0.15 mM monothioglycerol, 0.4 81 
ng/ml human erythropoietin, 10 ng/ml murine interleukin 3 and antibiotics. Cultures were 82 
maintained at 37°C in a humidified atmosphere containing 5% CO2. 83 
 84 
Reverse transcription PCR (RT-PCR)  85 
Total RNA was isolated from MKD1 cells or mouse heart using a High Pure RNA isolation kit 86 
from Roche (Burgess Hill, UK) following the manufacturer’s instructions. RT-PCR was performed 87 
with a GoScript reverse transcriptase kit from Promega (Southampton, UK) using following set of 88 
Rhobtb3-specific reverse primers for the cDNA synthesis reaction: GTPaseR, 89 
5’-TTCACTTGTCTTCTGATTTAAGGC-3’; E3R, 5’-ACTGTCAAAAATGTCCCAG-3’ and 90 
RhoBTB3R, 5’-TCACATGACTAAACAGCGACATTTCAG-3’. An aliquot of the cDNA synthesis 91 
reaction was used as template for a standard PCR with Rhobtb3 primers RhoBTB3F 92 
(5’-ATGTCCATCCACATCGTGGCG-3’) and GTPaseR spanning exons 2–5 to yield a 618-bp 93 
product. Expression of Gapdh was determined as housekeeping control with following primers: 94 
forward, 5′-AGGCCGGTGCGAGTATGTC-3′; reverse, 5′-TGCCTGCTTCACCACCTTCT-3′.  95 
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 96 
Experimental animals 97 
C57Bl/6 mice with a homozygous targeting of the Rhobtb3 gene have been described elsewhere 98 
[15]. The animals were kept in the animal facility of the University of Hull using standard 99 
conditions. All animal work was performed in accordance with UK Home Office regulations, UK 100 
Animals (Scientific Procedures) Act of 1986, under the Home Office project license no. PPL 60/4024. 101 
For all experiments age-matched wild type (WT) littermates were used as controls. 102 
 103 
Preparation of washed platelets 104 
Murine platelets were isolated as previously described [18]. Briefly, blood was taken by cardiac 105 
puncture into acid citrated dextrose (ACD) (113.8 mM D-glucose, 29.9 mM trisodium citrate, 72.6 106 
mM NaCl, 2.9 mM citric acid, pH 6.4), centrifuged at 100xg for 5 min and the platelet rich plasma 107 
(PRP) was collected in a separate tube. Modified Tyrode’s buffer (150 mM NaCl, 5 mM HEPES, 0.55 108 
mM NaH2PO4, 7 mM NaHCO3, 2.7 mM KCl, 0.5 mM MgCl2, 5.6 mM D-glucose, pH 7.4) was added 109 
to the blood and the procedure repeated in order to increase the platelet yield. The platelets were 110 
then pelleted at 800xg for 6 min, resuspended in modified Tyrode’s buffer and used for all 111 
consecutive experiments.  112 
 113 
Haematological measurements 114 
ACD-anticoagulated whole blood was diluted 1:20 in red blood cell lysis buffer (0.25 mM 115 
EDTA, 0.15 M NH4Cl, 0.01 M NaHCO3) for 1 min and 10 µl were transferred onto a Neubauer 116 
haemocytometer. White blood cells and platelets were counted in duplicate. Red blood cell counts 117 
and haematocrit were determined as described previously [19]. 118 
 119 
Flow cytometry 120 
PRP was prepared in sodium-citrate (110 mM trisodium citrate, pH 7.4). PRP was stimulated 121 
with CRP or ADP for 20 min at 37°C in the presence of FITC-conjugated anti-P-selectin (BD 122 
Biosciences, Oxford, UK) and PE-JON/A (Emfret, Würzburg, Germany). Platelets were 123 
subsequently fixed and analysed by fluorescence activated cell sorting (FACS) using a LSR Fortessa 124 
cell analyser (BD Biosciences, Oxford, UK). For receptor expression studies platelets were incubated 125 
with FITC-conjugated antibodies directed against surface membrane glycoproteins GP1b (CD42b), 126 
GPVI, integrin α2 (CD49b) (Emfret, Eibelstadt, Germany) and integrin αIIb (CD41) (BD Biosciences, 127 
Oxford, UK). Receptor expression was also studied upon stimulation with 0.1 U/ml thrombin for 20 128 
min at 37°C in the presence of 10 µM Gly-Pro-Arg-Pro-NH2. Platelets were subsequently analysed 129 
by FACS. 130 
 131 
Platelet aggregation and adhesion 132 
Platelet aggregation in response to agonists was recorded under constant stirring conditions 133 
(1000 rpm) for 4 min at 37°C using Born aggregometry. For adhesion studies coverslips were coated 134 
overnight at 4°C with fibrinogen, collagen, CRP or GFOGER at the concentrations indicated and 135 
blocked with heat denatured fatty acid free bovine serum albumin for 1 h before the experiment. 136 
Washed platelets were allowed to spread for 1 h, fixed with 4% paraformaldehyde (PFA), 137 
permeabilised with 0.3% Triton X-100 and stained with TRITC-labelled phalloidin. Platelets were 138 
imaged by fluorescence microscopy using a Zeiss ApoTome.2 equipped with an AxioCam 506 and 139 
a Zeiss Plan-Apochromat 63x NA 1.4 objective. Platelets were manually counted and the surface 140 
coverage area was analysed by thresholding using FIJI (ImageJ). 141 
 142 
Lumiaggregometry 143 
ATP release was measured using Chrono-lume firefly luciferin/luciferase reagent (Chrono-Log, 144 
Havertown, PA). Washed platelets (2.5x108 platelets/ml) were incubated at 37°C for 5 min in a 145 
Chrono-log lumiaggregometer (Pennsylvania, USA) under non-stirring conditions. Chrono-lume 146 
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was added for 2 min, followed by stimulation with thrombin under stirring conditions (1000 rpm). 147 
Secretion traces were recorded for 5 min.  148 
 149 
Electron microscopy 150 
Washed platelets were fixed in 0.1% glutaraldehyde in White’s saline (0.6 M NaCl, 5 mM KCl, 151 
3.8 mM MgSO4, 4.5 mM Ca(NO3)2, 6.5 mM NaHCO3, 0.35 mM Na2HPO4, 0.19 mM KH2PO4, 0.5 mg 152 
phenol red) and processed as described elsewhere [20]. Thin sections were cut with a diamond 153 
knife on an ultra-microtome. Samples were visualised with a JEOL 2010 transmission electron 154 
microscope equipped with a Gatan Ultra Scan 4000 camera. 155 
 156 
Arterial flow experiments 157 
Whole murine blood containing 40 µM PPACK was stained with 1 µM DiOC6 for 10 min at 158 
37°C. Blood was then perfused through 50 µg/ml collagen or 1 mg/ml fibrinogen coated capillary 159 
tubes at a shear rate of 1000 s-1 for 2 min and images of stably adhered platelets/thrombi were 160 
captured as previously described [18]. Thrombus volume was measured as previously described 161 
[21]. 162 
 163 
Tail bleeding assay 164 
Mice were anesthetised with 5 mg/kg thiopental (Link Pharmaceuticals, Horsham, UK). The 165 
tail was cut off at 3 mm from the tip and immediately immersed in 37°C saline (0.9% v/w NaCl). 166 
Bleeding time was monitored until haemostasis for up to 10 min. 167 
 168 
Statistical analysis 169 
Experimental data was analysed by Graphpad Prism v6.0 (LA Jolla, USA). Data are presented 170 
as means ± standard error of the mean (SEM) or standard deviation (SD) of at least 3 independent 171 
experiments. Normality was assessed by the Shapiro-Wilk test. Differences between groups were 172 
assessed using the Student’s t-test, Mann-Whitney U-test or ANOVA and statistical significance 173 
taken at P≤0.05.  174 
  175 
3. Results 176 
3.1. Rhobtb3 mRNA is present in mouse megakaryocytes  177 
Despite extensive efforts with several commercial and custom made antibodies, we were not 178 
able to detect RhoBTB3 protein in platelet and megakaryocyte lysates, which we attribute to poor 179 
antibody quality as well as low levels of the protein being expressed in platelets (data not shown). 180 
Of note, a literature survey shows that available antibodies fail to recognize any endogenous 181 
RhoBTB in fixed cells and tissues and very seldom in cell lysates [12]. Low protein levels and the 182 
fact that RhoBTB3 is a predominantly Golgi protein and very little Golgi is present in mature 183 
platelets may explain why platelet proteomics data fails to detect RhoBTB3 in mouse or human 184 
platelets [22][23].  185 
To verify the expression of Rhobtb3 in the megakaryocyte cell lineage we extracted RNA from 186 
the embryonic stem cell derived murine megakaryocyte cell line MKD1 [17]. This approach was 187 
considered superior to using primary murine megakaryocytes in terms of amount of material and, 188 
more importantly, cell type homogeneity. Using RT-PCR with specific reverse primers we were able 189 
to detect Rhobtb3 mRNA in MKD1 cells (Figure 1). The PCR reaction yielded the expected 618-bp 190 
product in both MDK1 and mouse heart cDNA as previously described [15]. We therefore conclude 191 
that Rhobtb3 is expressed in cells of the megakaryocytic lineage. This result is consistent with the 192 
presence of RhoBTB3 encoding transcripts in mouse platelet transcriptomics studies [16]. 193 
 194 
 195 
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 196 
Figure 1. Expression of Rhobtb3 in a mouse megakaryocyte cell line. RT-PCR was performed on 197 
RNA extracted form the mouse megakaryocyte cell line MKD1 (lane 3) or mouse adult heart (lane 198 
4). The cDNA synthesis was done with a mix of reverse Rhobtb3-specific primers and the PCR with 199 
Rhobtb3 primers spanning exons 2–5 to yield a 618-bp product. A cDNA synthesis with a reverse 200 
Gapdh primer was done on MKD1 RNA followed with a PCR with primers to yield a 530-bp product 201 
corresponding to the house-keeping gene Gapdh (lane 5). Lane 1 is a PCR control reaction with 202 
Rhobtb3 and Gapdh primers and no template. Lane 2 is a PCR reaction with Rhobtb3 primers and the 203 
product of a cDNA synthesis performed with MKD1 RNA and Rhobtb3 primers but without reverse 204 
transcriptase. L, ladder. 205 
3.2. Receptor expression is unaffected in RhoBTB3 deficient platelets 206 
We hypothesised that RhoBTB3 may play roles in Golgi function in megakaryocytes during platelet 207 
formation, prompting us to study the effect of Rhobtb3 gene disruption in platelet morphology and 208 
function in a RhoBTB3 KO mouse model characterised by our group previously [15]. 209 
Haematological evaluation of RhoBTB3 KO animals indicated that haematopoiesis is not affected, 210 
as evidenced by similar red blood cell, leukocyte and platelet counts to WT littermates (Table 1). 211 
The size of RhoBTB3 KO platelets was comparable to that of WT platelets as measured in the 212 
forward light scatter of flow cytometry experiments (p = 0.62, Student’s t test) (Figure 2A). 213 
Table 1. Haematology features of RhoBTB3 deficient mice. Counts were assessed with a Neubauer 214 
counting chamber. Haematocrit is expressed as percentage fraction of total. Data represents the 215 
average ± SD from 10 (haematocrit) or 11 (cell counts) animals of each genotype. P values are 216 
calculated from Student’s t tests. 217 
 RhoBTB3 WT RhoBTB3 KO  P value 
Red blood cells (µl-1) 9,842,237 ± 1,414,027  9,994,156 ± 1,953,946 0.84 
White blood cells (µl-1) 7923 ± 3021 7464 ± 2796 0.72 
Platelets (µl-1) 951,602 ± 407,511 847,438 ± 163,831  0.46 
Haematocrit 47 ± 11 46 ± 15 0.92 
 218 
When we assessed the expression of characteristic surface platelet receptors (GPVI, CD41, CD42b 219 
and CD49b) by FACS we found no significant alterations (Figure 2B). We also investigated whether 220 
platelet activation with thrombin would reveal any effect in the receptors’ behaviour in RhoBTB KO 221 
platelets that could be related to a participation of this protein in vesicle trafficking events. 222 
Thrombin stimulation caused a modest but significant increase in the expression of GPVI and CD41 223 
(18-22%) and CD49b (4-8%). A more profound decrease in the expression of CD42b (32-40%) was 224 
observed, due to cleavage and internalization of the GP1b/IX/V complex [24]. However those effects 225 
were comparable in RhoBTB3 WT and KO platelets (Figure 2). We conclude that RhoBTB3 is 226 
dispensable for platelet production and surface receptor expression. 227 
 228 
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 229 
Figure 2. Relative size and receptor expression in RhoBTB3 deficient platelets. A. Mean platelet 230 
volume (MPV) was measured by median forward light scatter height using flow cytometry. Data 231 
represents average ± SEM of 6 independent experiments. B. Platelet surface receptors were 232 
determined by flow cytometry both in basal conditions (B) and upon stimulation with 0.1 U/ml 233 
thrombin for 20 minutes. Data represents average ± SEM of 6 independent experiments. * p<0.05; *** 234 
p<0.001; paired Student’s t-test between basal and stimulated conditions. No significant differences 235 
were observed between WT and KO platelets (non paired Student’s t-test). 236 
3.3. Secretion from alpha granules is altered in RhoBTB3 deficient platelets 237 
RhoBTB3 has been implicated in intracellular vesicle trafficking and therefore we hypothesised that 238 
granular morphology and degranulation might be defective in RhoBTB3 KO platelets [12,25]. We 239 
assessed the platelet ultrastructure by transmission electron microscopy to identify potential 240 
morphological alterations. Within a wide range of size and shape variability, we did not observe 241 
any difference between WT and KO platelets (Figure 3A). Alpha and dense granule distribution 242 
appeared not to be affected by ablation of Rhobtb3 (alpha granules per platelet: 2.97 ± 0.43 in WT vs. 243 
2.84 ± 0.21 in KO, p = 0.77; dense granules per platelet: 1.80 ± 0.12 in WT vs. 1.81 ± 0.16 in KO, p = 244 
0.92) (Figure 3B). We set out to explore whether, despite a similar morphology, RhoBTB3 KO 245 
platelets have a defect in granule secretion. To monitor alpha granule secretion we induced platelet 246 
P-selectin expression by haemostatic agonists of varying potency (thrombin, CRP and a 247 
combination of ADP and the thromboxane analog U46619). A trend towards increased response 248 
was observed with all agonists that reached statistical significance with 0.02 U/ml thrombin (p = 249 
0.0152), 10 µg/ml CRP (p = 0.0152) and the synergistic combination of 10 µM ADP and 3 µM U46619 250 
(p = 0.0411) (Figure 3C). Next we assessed dense granule secretion by ATP luminometry in response 251 
to varying doses (0.025 and 0.05 U/ml) of thrombin stimulation. None of the conditions tested 252 
revealed any significant difference in ATP secretion (Figure 3D).  253 
 254 




Figure 3. Ultrastructure and secretion in RhoBTB3 deficient platelets A. Representative images of 257 
platelet ultrastructure of RhoBTB3 KO and WT mice. DG, dense granule; αG, alpha granule. B. 258 
Quantification of the number of alpha and dense granules per platelet. Data was obtained from 259 
transmission electron micrographs. Only entire platelets were scored. Data represent average ± SD 260 
of 100-200 platelets from 3 independent preparations. C. P-selectin expression (median fluorescence 261 
intensity, MFI) of either resting or stimulated platelets from 5 µl of whole blood with the indicated 262 
doses of thrombin, CRP or a combination of ADP and U46619. The data represent the 263 
average ± SEM of 6 independent experiments. * p<0.05; Mann-Whitney U-test. D. ATP secretion 264 
upon thrombin stimulation. Washed platelets (2.5 x 108 platelets/ml) were incubated at 37°C in a 265 
Chronolog lumiaggregometer in the presence of Chrono-lume for 2 min, followed by stimulation 266 
with the indicated doses of thrombin. Secretion traces were recorded for 5 min and used to calculate 267 
the percentage of ATP secretion. The data represent the mean ± SEM of 3 independent experiments. 268 
 269 
3.4. RhoBTB3 deficient platelets show normal integrin αIIbβ3 activation and aggregation 270 
The potential effects of RhoBTB3 deficiency on integrin αIIbβ3 activation were assessed indirectly by 271 
Born aggregometry and directly by the activation state-specific antibody JON/A by FACS. Collagen 272 
(2.5-10 µg/ml), thrombin (0.0125, 0.025 and 0.1 U/ml) and ADP (10 µM) all induced aggregation of 273 
washed platelets isolated from RhoBTB3 KO mice, which was of similar extent to that observed 274 
with WT platelets (Figure 4A). Using a more sensitive FACS approach RhoBTB3 KO platelets 275 
treated with a range of agonists ADP (1 and10 µM) and CRP (1 and 10 µg/ml) caused activation of 276 
αIIbβ3 as evidenced by increased binding of JON/A. However, we were not able to detect any 277 
significant differences in the αIIbβ3 activatory state between RhoBTB3 KO and WT platelets (Figure 278 
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4B). Therefore, RhoBTB3 appears to be dispensable for αIIbβ3 activation and subsequent platelet 279 




Figure 4. Normal aggregation and αIIbβ3 integrin activation in RhoBTB3 deficient platelets. A. 284 
Washed platelets (2.0 x 108 platelets/ml) were stimulated with the indicated doses of collagen, 285 
thrombin or ADP and aggregation was recorded under constant stirring conditions (1000 rpm) for 4 286 
min at 37°C in a Chronolog aggregometer. Traces are representative of 3 independent experiments. 287 
B. Integrin activation (median fluorescence intensity, MFI) upon platelet stimulation from 5 µl of 288 
whole blood for 20 min with the indicated doses of ADP or CRP and subsequent analysis on flow 289 
cytometry. The data represent the mean ± SEM of 3 independent experiments. 290 
3.5.Defective accrual of Rhobtb3 deficient platelets on a collagen matrix under arterial flow  291 
We next sought to explore platelets spreading in a physiologically relevant context under 292 
conditions of arterial blood flow. Perfusion of whole blood under arterial shear over a fibrinogen 293 
matrix led to platelet accrual and formation of a monolayer. Under these conditions the surface 294 
coverage with WT and KO blood at the end of the observation period was indistinguishable (18.12 ± 295 
0.72% in the KO vs. 19.27 ± 1.29% in the WT, p = 0.44). In contrast we observed that on collagen less 296 
platelets from KO blood adhered compared to WT resulting in a reduced surface coverage at the 297 
end of the observation period (8.9 ± 0.7% in the KO vs. 13.8 ± 0.8% in the WT, p<0.0001; 298 
Mann-Whitney U-test) (Figure 5A,B). To investigate the dynamics of adhesion to collagen and 299 
thrombus volume accrual under flow we plotted the fluorescence intensity as a function of time and 300 
found that with RhoBTB3 KO platelets adhesion and thrombus volume increase occurred at a lower 301 
rate during the complete period of observation (area under the curve: WT 5082 AU vs. KO 2848 302 
AU) (Figure 5C). In summary, genetic deletion of Rhobtb3 led to a reduced adhesion to collagen 303 
under arterial flow conditions. 304 
 305 
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 306 
Figure 5. Behaviour of RhoBTB3 KO and WT platelets on collagen or fibrinogen coated surfaces 307 
under flow. A. Whole blood was stained with 1 µM DiOC6 for 10 min at 37°C and perfused through 308 
50 µg/ml collagen or 1 mg/ml fibrinogen coated capillary tubes at a shear rate of 1000 s-1 for 2 min. 309 
Representative images after 2 min are shown. B. Quantification of surface coverage. Data are 310 
average ± SEM of images like those of panel A from 3 (fibrinogen) or 4 (collagen) independent 311 
experiments after 10 min of perfusion. *** p<0.001, Mann-Whitney U-test. C. Adhesion of platelets to 312 
collagen under flow as a function of time. Fluorescence intensity was calculated from images like 313 
those of panel A by thresholding using ImageJ. Data are average ± SEM of 4 independent 314 
experiments. 315 
To narrow down the adhesion defect observed under conditions of arterial flow, we investigated 316 
platelet adhesion and spreading on surfaces coated with collagen (100 µg/ml) or fibrinogen (1000 317 
and 100 µg/ml). Slightly, although statistically not significantly, more WT platelets per observation 318 
field adhered on fibrinogen (123.3 ± 21.0 on 1000 µg/ml and 107.4 ± 10.2 on 100 µg/ml) than on 319 
collagen (98.3 ± 14.3). However, there was no difference in the number of platelets adhering to 320 
either surface between the WT and the genetically modified mice (105.6 ± 24.1, 113.9 ± 15.0 on 321 
fibrinogen and 89.3 ± 12.7 on collagen) (Figure 6A, B). Detailed examination of the spread platelets 322 
revealed that both WT and KO platelets covered a slightly (but not significantly) larger surface on 323 
collagen (13.01 ± 1.32 µm2 in the WT vs. 13.71 ± 1.65 µm2 in the KO) than on fibrinogen (11.20 ± 0.92 324 
µm2 in the WT vs. 11.31 ± 1.55 µm2 in the KO for 100 µg/ml; similar values for 1000 µg/ml) (Figure 325 
6C). On collagen platelets displayed prominent stress fibres and the cells often appeared stretching 326 
along matrix fibres, whereas on both concentrations of fibrinogen (only 100 µg/ml shown as an 327 
example in Figure 5A) platelets showed abundant filopods and actin nodules. No noticeable 328 
differences between WT and KO platelets were apparent in the morphology in any of the matrices. 329 
 330 
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 331 
Figure 6. Unimpaired spreading of RhoBTB3 deficient platelets. A. Adhesion of RhoBTB3 KO and 332 
WT platelets to glass coverslips coated with the indicated concentration of collagen, fibrinogen, 333 
GFOGER or CRP. Adherent platelets were fixed with 4% PFA, permeabilised with 0.3% Triton X-100 334 
and stained with TRITC-phalloidin. Platelets were visualised with a fluorescence microscope and 335 
images of random areas were acquired. For each phenotype the right column shows examples of 336 
platelets at higher magnification. Scale bars represent 5 µm. B. Number of platelets adhering to the 337 
indicated concentrations of collagen, fibrinogen, GFOGER or CRP. 10 fields each 12500 µm2 from 338 
5-10 independent experiments were counted per condition. Data represents average ± SEM. No 339 
significant differences were found between WT and KO platelets for any condition (Mann-Whitney 340 
U-test). C. Surface coverage per platelet calculated by thresholding using ImageJ. Data represent 341 
average ± SEM from 5-10 independent experiments and 250-1000 platelets per condition for each 342 
experiment. No significant differences were found between WT and KO platelets for any condition 343 
(Mann-Whitney U-test). 344 
Platelet adhesion to collagen is mediated by two different receptors, GPVI and α2β1 integrin. To 345 
narrow down the accrual defect we observed under flow conditions to a potential defect in one of 346 
Cells 2019, 8, x FOR PEER REVIEW 11 of 16 
 
those receptors we investigated adhesion and spreading to various concentrations of peptides that 347 
specifically bind to one receptor, GFOGER (for α2β1) and CRP (for GPVI) (Figure 6). In general, less 348 
platelets adhered on GFOGER compared to collagen, in a matrix concentration dependent manner, 349 
down to approximately 50% at the lowest matrix concentration. The trend was similar in both WT 350 
and KO platelets. Significantly less platelets (16.4 ± 2.7 in the WT vs. 17.6 ± 4.4 at the lowest matrix 351 
concentration) adhered on CRP compared to the respective spreading data on collagen (p= 0.001) 352 
(Figure 5B). Surface coverage was slightly lower on GFOGER (10.52 ± 0.25 µm2 in the WT vs 10.41 ± 353 
0.31 µm2 in the KO at the lowest matrix concentration) and higher on CRP (14.95 ± 1.97 µm2 in the 354 
WT vs KO 16.90 ± 1.10 µm2 in the KO at the lowest matrix concentration) compared to collagen, but 355 
these differences did not reach statistical significance (Figure 6C). While platelets on CRP 356 
morphologically resembled the ones on collagen, on GFOGER they looked more discoid and 357 
displayed long, thick and sometimes branched filopods (Figure 6A shows examples at intermediate 358 
matrix protein concentrations). No significant differences between WT and KO were found in the 359 
platelet numbers, surface covered and morphology on any of the two receptor-specific matrices at 360 




Figure 7. Tail bleeding time. Tests were performed by cutting off 3 mm of the tail tip and placing 365 
the tail in 37°C saline. The time until haemostasis was recorded for up to 10 min and re-bleeding 366 
monitored for 60 sec beyond haemostasis. Data represent average ± SD of 12-13 animals. 367 
Finally, in order to evaluate the influence of Rhobtb3 deletion on haemostasis, tail bleeding time 368 
was examined (Figure 7). Both RhoBTB3 KO and WT animals showed a comparable average 369 
bleeding time (KO 3.06 ± 2.48 vs. WT 2.51 ± 1.90; p = 0.97, Student’s t test). 370 
  371 
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4. Discussion 372 
Recent studies in animal and pharmacological models have significantly contributed to 373 
elucidate the roles of Rho GTPase signalling in platelet function. Although we still lack a clear 374 
picture, these studies have revealed the participation of major Rho GTPases, like Rac1, Cdc42 and 375 
RhoA, as well as some of their effectors and regulators in various key platelet biology processes 376 
[2,3]. Comparatively little is known about the roles of atypical Rho GTPases in general, and 377 
virtually nothing in platelets. Here we contribute to our understanding of the potential relevance of 378 
RhoBTB3 using a KO mouse model for an in depth characterisation of platelet function. The salient 379 
features of the genetic deletion of Rhobtb3 are increased alpha granule secretion and reduced 380 
accrual to collagen under low arterial shear conditions in the absence of any other overt 381 
morphological or functional alteration.  382 
 383 
RhoBTB3 is itself a substrate for the cullin 3-based ubiquitin ligase complexes it helps recruit, 384 
and therefore it doesn’t appear to accumulate [26]. Platelets possess an active 385 
proteasome-dependent degradation machinery [27], which linked to the fact that RhoBTB3 is a 386 
predominantly Golgi protein and very little Golgi is transmitted to platelets during thrombopoiesis 387 
[28] would explain the undetectable levels of this protein in mature platelets with the available 388 
tools. Nevertheless, RhoBTB3 may play roles in Golgi function in megakaryocytes during platelet 389 
formation, therefore any defect observable in platelets would be mainly the result of a qualitatively 390 
defective platelet biogenesis [29]. We exclude any quantitative defect in haematopoeisis since 391 
RhoBTB3 deficiency does not affect the production of platelets and other blood cells as shown by 392 
unaltered blood counts and platelet size. 393 
 394 
RhoBTB3 has been shown to specifically interact with Rab9, which localises to late endosomes 395 
and is required for lysosome biogenesis [13,30]. Loss of Rab9 or its effectors RhoBTB3, TIP47 and 396 
GCC185 results in mis-sorting of mannose-6-phosphate receptors to lysosomes [13]. Interestingly, 397 
Rab9 also interacts with BLOC-3 (biogenesis of lysosome-related organelles complex-3). Mutations 398 
in BLOC-3 have been identified in patients with Hermansky-Pudlak syndrome, who suffer from 399 
bleeding due to defective biogenesis of lysosome related organelles such as dense granules [31]. We 400 
have not noticed any morphological defects in dense and alpha granules while also dense granule 401 
secretion appeared to be unaffected. However, we observed an increased reactivity in RhoBTB3 402 
deficient platelets by P-selectin exposure upon stimulation with various agonists that was not 403 
accompanied by increased αIIbβ3 activation. It is not unusual that a defect in alpha granules does not 404 
affect αIIbβ3 as reported in storage pool deficient platelets from humans, which do not necessarily 405 
show a platelet aggregation defect in vitro [32]. RhoBTB3 apparently affects solely alpha-granule 406 
secretion and this effect might be traced back to a role of RhoBTB3 in vesicle trafficking during 407 
platelet biogenesis [12]. 408 
 409 
Similar phenotypes have been described before that link the observation of increased P-selectin 410 
expression to decreased adhesion to collagen. In a double KO for multimerin and alpha-synuclein 411 
Reheman et al. found increased levels of P-selectin upon thrombin stimulation accompanied by a 412 
decreased accrual on collagen under flow [33]. In the original phenotypical description of the Cdc42 413 
KO mouse an approximately 10% decrease in percentage surface coverage on collagen was 414 
reported, while P-selectin expression was found increased [5]. Interestingly, in a double KO mouse 415 
of the related actin-binding proteins cortactin and its homolog haematopoietic lineage cell-specific 416 
protein 1 (HS1) the only salient defect was impaired accrual on collagen under high shear rates [34]. 417 
A fraction of RhoBTB3 localises to early endosomes [26], where it may interact with Hrs (hepatocyte 418 
growth factor-regulated tyrosine kinase substrate) [35], a subunit of the ESCRT-0 complex that 419 
captures ubiquitinated membrane proteins and mediates their recycling and retrograde trafficking 420 
[36]. Receptor recycling in general, and integrin recycling in particular, remains poorly understood 421 
in platelets. Different integrins follow distinct recycling mechanisms and routes [37] and a recent 422 
study has showed that disturbed recycling of integrin αIIbβ3 with an inhibitor of clathrin-mediated 423 
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endocytosis impaired spreading on fibrinogen [38], highlighting the importance of integrin 424 
recycling in platelets. Interestingly, we observe alterations in the adhesion to collagen, but not to 425 
fibrinogen, under flow conditions. We speculate that despite unaltered collagen receptor numbers 426 
α2β1 and/or GPVI may be sub-functional due to delayed turnover, impaired recycling or impaired 427 
signalling. In this respect signalling through GPVI involves the Fcγ receptor as well as non-receptor 428 
tyrosine kinases of the Src family whose localisation and signalling activities are tightly regulated 429 
by endocytic trafficking in various cell types [39,40].  430 
 431 
In summary, we show that the loss of RhoBTB3 is associated with altered alpha granule 432 
secretion and a defect in collagen-mediated accrual, which might be a testimony of the roles of this 433 
protein in vesicle trafficking processes during platelet biogenesis. Despite these alterations, 434 
bleeding time is not affected, making RhoBTB3 dispensable for haemostasis. 435 
 436 
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